Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Abu Dhabi Health Department Partners with Sanofi to Establish Vaccine Innovation Center in HELM Cluster

Fineline Cube Jun 25, 2026
Company Deals

YHLO Biotech and Jingyi Bio Forge Strategic Alliance to Advance Neuroimmunology Diagnostics – Expanding Autoimmune Testing into Neurological Disorders

Fineline Cube Jun 24, 2026
Company Deals

Fusen Pharmaceutical Secures RMB 300M Strategic Investment for Henan Subsidiary Debt Restructuring and Working Capital

Fineline Cube Jun 24, 2026
Company Deals

AbbVie to Acquire Apogee Therapeutics for $10.9B to Expand Inflammatory Disease Pipeline

Fineline Cube Jun 24, 2026
Company Deals

BioArctic Partners with Eli Lilly on Novel Neurodegenerative Disease Therapy Using BrainTransporter Platform

Fineline Cube Jun 23, 2026
Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026
Company Drug

Mabwell Bioscience Secures NMPA Approval for 9MW5211 Clinical Trial in Multiple Sclerosis – Expanding Autoimmune Pipeline

Fineline Cube Jun 25, 2026
Company Drug

Takeda Secures NMPA Approval for Adzynma – China’s First Recombinant ADAMTS13 Therapy for Congenital TTP

Fineline Cube Jun 25, 2026
Policy / Regulatory

Guangzhou and Zhuhai Unveil Measures to Stimulate Biopharmaceutical Industry Growth

Fineline Cube Apr 8, 2024

In a bid to bolster the biopharmaceutical and health industries, the cities of Guangzhou and...

Company Drug

AstraZeneca and Daiichi Sankyo’s Enhertu Secures FDA Approval for HER2-Positive Solid Tumors

Fineline Cube Apr 8, 2024

Partners AstraZeneca (AZ; NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568) have been granted an additional...

Company Drug

Bristol Myers Squibb’s Abecma Receives FDA Approval for Wider Use in Multiple Myeloma Treatment

Fineline Cube Apr 8, 2024

The US Food and Drug Administration (FDA) has granted an indication extension for Bristol Myers...

Company

Sanofi Announces Sweeping Restructuring and Layoffs in Pipeline Reprioritization Effort

Fineline Cube Apr 8, 2024

Paris-based pharmaceutical giant Sanofi (NASDAQ: SNY) is embarking on a comprehensive “full pipeline reprioritization” that...

Company Drug

Dizal Pharmaceutical’s Sunvozertinib Earns FDA Breakthrough Therapy Designation for NSCLC

Fineline Cube Apr 8, 2024

Dizal Pharmaceutical Co., Ltd (SHA: 688192), a leading Chinese pharmaceutical company, has announced that its...

Company Deals

Sino Biopharmaceutical Partners with Boehringer Ingelheim to Bring Innovative Cancer Therapies to China

Fineline Cube Apr 8, 2024

Sino Biopharmaceutical Ltd (HKG: 1177) has announced a strategic partnership with Germany’s Boehringer Ingelheim (BI)...

Company Drug

Sichuan Kelun-Biotech Presents Positive Results for Sacituzumab Tirumotecan at AACR 2024

Fineline Cube Apr 8, 2024

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) has announced the presentation of favorable results from...

Company Deals R&D

Zhejiang Dian Diagnostics Partners with Hangzhou Medical College to Establish Education Base

Fineline Cube Apr 8, 2024

Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244), a prominent player in the medical diagnostics space,...

Company Deals

Applied Protein Technology Secures Series C Financing to Accelerate Multi-Omics Innovation

Fineline Cube Apr 8, 2024

Shanghai-based Applied Protein Technology (APTBIO), a pioneer in life science technology services driven by mass...

Company Drug

Huadong Medicine Gets NMPA Approval for Clinical Trial of FRα-Targeting ADC Elahere

Fineline Cube Apr 8, 2024

China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that it has received approval from...

Company Drug

Hinova Pharmaceuticals Receives NMPA Greenlight for HP501 Clinical Trial in Gout Patients

Fineline Cube Apr 8, 2024

Shanghai-based Hinova Pharmaceuticals Inc. (SHA: 688302) has announced that it has received approval from the...

Company Drug

Junshi Biosciences’ Toripalimab Approved for First-Line RCC Treatment in China

Fineline Cube Apr 8, 2024

Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180) has received a new indication approval...

Company Drug

Ascletis Pharma Halts ASC42 Phase II Study in Primary Biliary Cholangitis

Fineline Cube Apr 7, 2024

China-based Ascletis Pharma Inc. (HKG: 1672) has announced its decision to terminate the Phase II...

Company Drug

IASO Biotherapeutics Gains FDA Nod for Fucaso CAR-T Study in Myasthenia Gravis

Fineline Cube Apr 7, 2024

China-based IASO Biotherapeutics has received approval from the U.S. Food and Drug Administration (FDA) to...

Company Drug

Ipsen Secures NMPA Approval for Somatuline in Advanced Neuroendocrine Tumors

Fineline Cube Apr 7, 2024

Ipsen (EPA: IPN; OTCMKTS: IPSEY), a France-based biopharmaceutical company, has received new indication approval from...

Company Drug

Shanghai Henlius Reports Phase III Success for HLX14 in Osteoporosis Treatment

Fineline Cube Apr 7, 2024

Shanghai Henlius Biotech Inc. (HKG: 2696), based in China, has announced that its global, multi-center...

Company Deals

Siemens Healthineers and Siemens China Partner with Fudan Hospital Logistic Service on Green Imaging Centers

Fineline Cube Apr 7, 2024

Germany-based Siemens Healthineers AG, along with its subsidiary Siemens China, has entered into a strategic...

Company Drug

Mabwell Bioscience Receives NMPA Approval for Biosimilar Version of Amgen’s Xgeva

Fineline Cube Apr 7, 2024

Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced that it has received market approval...

Company Drug

Walvax Biotechnology’s COVID-19 Variant Vaccine RQ3033 Shows Positive Phase III Results

Fineline Cube Apr 7, 2024

China-based Walvax Biotechnology Co., Ltd (SHE: 300142) has announced positive results from a Phase III...

Company Deals

Eisai Forges Strategic Partnership with China Resource Medicine and China Resources Sanjiu for Pharmaceutical Collaboration

Fineline Cube Apr 7, 2024

Japanese pharmaceutical company Eisai (TYO: 4523) has entered into a cooperation agreement with China Resource...

Posts pagination

1 … 400 401 402 … 688

Recent updates

  • China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs
  • NHSA Advances Record 674 Drugs in 2026 Insurance Catalog Review with 92% Preliminary Pass Rate
  • Mabwell Bioscience Secures NMPA Approval for 9MW5211 Clinical Trial in Multiple Sclerosis – Expanding Autoimmune Pipeline
  • Abu Dhabi Health Department Partners with Sanofi to Establish Vaccine Innovation Center in HELM Cluster
  • Takeda Secures NMPA Approval for Adzynma – China’s First Recombinant ADAMTS13 Therapy for Congenital TTP
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Policy / Regulatory

NHSA Advances Record 674 Drugs in 2026 Insurance Catalog Review with 92% Preliminary Pass Rate

Company Drug

Mabwell Bioscience Secures NMPA Approval for 9MW5211 Clinical Trial in Multiple Sclerosis – Expanding Autoimmune Pipeline

Company Deals

Abu Dhabi Health Department Partners with Sanofi to Establish Vaccine Innovation Center in HELM Cluster

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.